Stay updated with breaking news from Editha Perez. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Updated safety data supports the selection of 20 mg/kg q2w as the recommended Phase 2 dose Improved efficacy with one partial response improving to a complete response , two additional patients with...
BDC-3042, a novel Dectin-2 agonistic antibody that stimulates the innate immune system, is being evaluated in a Phase 1/2 dose-escalation and expansion study in patients with a broad range of solid...
REDWOOD CITY, Calif., Oct. 16, 2023 -- Bolt Biotherapeutics, Inc. , a clinical-stage biopharmaceutical company pioneering novel immuno-oncology therapeutics for the treatment of cancer, today...
The FDA has given an orphan drug designation to BDC-1001 for the treatment of patients with gastric cancers, including gastroesophageal junction cancer.
The first patients have been dosed in the phase 2 portion of a phase 1/2 trial evaluating BDC-1001 monotherapy in patients with HER2-positive colorectal cancer, endometrial cancer, and gastroesophageal cancer.